Nektar Therapeutics Stock Rockets 19% on Strong 52-Week Alopecia Areata Data for Lead Drug Candidate
- Posted on April 20, 2026
- By International Business Times
- 0 Views
- 1 min read
Nektar Therapeutics Stock Rockets 19% on Strong 52-Week Alopecia Areata Data for Lead Drug Candidate
Shares of Nektar Therapeutics surged more than 19% in early Monday trading on April 20, 2026, climbing $16.58 to $101.44 as investors cheered positive 52-week topline results from the Phase 2b REZOLVE-AA clinical trial of the company's lead immunology candidate, rezpegaldesleukin, in patients with
